期刊
LANCET HIV
卷 8, 期 8, 页码 E474-E485出版社
ELSEVIER INC
DOI: 10.1016/S2352-3018(21)00103-X
关键词
-
资金
- UK Research and Innovation [MC_PC_19055]
- Engineering and Physical Sciences Research Council [EP/R013756/1]
- Coalition for Epidemic Preparedness Innovations
- NIHR
- Thames Valley
- South Midland's NIHR Clinical Research Network
- NIHR Oxford Health Biomedical Research Centre
- AstraZeneca
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil [001]
- Chinese Academy of Medical Sciences Innovation Fund for Medical Science, China [2018-I2M-2-002]
- Wellcome Trust
- Royal Society [220171/Z/20/Z]
The study demonstrates that the ChAdOx1 nCoV-19 vaccine is safe and immunogenic in people with HIV, with no serious adverse events reported. Local and systemic reactions were similar to those in HIV-negative participants, and antibody and cellular immune responses in HIV-infected individuals showed similar levels to those in uninfected individuals.
Background Data on vaccine immunogenicity against SARS-CoV-2 are needed for the 40 million people globally living with HIV who might have less functional immunity and more associated comorbidities than the general population. We aimed to explore safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in people with HIV. Methods In this single-arm open-label vaccination substudy within the protocol of the larger phase 2/3 trial COV002, adults aged 18-55 years with HIV were enrolled at two HIV clinics in London, UK. Eligible participants were required to be on antiretroviral therapy (ART), with undetectable plasma HIV viral loads ( 50 copies per mL), and CD4 counts of more than 350 cells per mu L. A prime-boost regimen of ChAdOx1 nCoV-19, with two doses was given 4-6 weeks apart. The primary outcomes for this substudy were safety and reactogenicity of the vaccine, as determined by serious adverse events and solicited local and systemic reactions. Humoral responses were measured by anti-spike IgG ELISA and antibody-mediated live virus neutralisation. Cell-mediated immune responses were measured by ex-vivo IFN-gamma enzyme linked immunospot assay (ELISpot) and T-cell proliferation. All outcomes were compared with an HIV-uninfected group from the main COV002 study within the same age group and dosing strategy and are reported until day 56 after prime vaccination. Outcomes were analysed in all participants who received both doses and with available samples. The COV002 study is registered with ClinicalTrials.gov, NCT04400838, and is ongoing. Findings Between Nov 5 and Nov 24, 2020, 54 participants with HIV (all male, median age 42.5 years [IQR 37.2-49.8]) were enrolled and received two doses of ChAdOx1 nCoV-19. Median CD4 count at enrolment was 694.0 cells per mu L (IQR 573.5-859.5). No serious adverse events occurred. Local and systemic reactions occurring during the first 7 days after prime vaccination included pain at the injection site (26 [49%] of 53 participants with available data), fatigue (25 [47%]), headache (25 [47%]), malaise (18 [34%]), chills (12 [23%]), muscle ache (19 [36%]), joint pain (five [9%]), and nausea (four [8%]), the frequencies of which were similar to the HIV-negative participants. Anti-spike IgG responses by ELISA peaked at day 42 (median 1440 ELISA units [EUs; IQR 704-2728]; n=50) and were sustained until day 56 (median 941 EUs [531-1445]; n=49). We found no correlation between the magnitude of the anti-spike IgG response at day 56 and CD4 cell count (p=0.93) or age (p=0.48). ELISpot and T-cell proliferative responses peaked at day 14 and 28 after prime dose and were sustained to day 56. Compared with participants without HIV, we found no difference in magnitude or persistence of SARS-CoV-2 spike-specific humoral or cellular responses (p 0.05 for all analyses). Interpretation In this study of people with HIV, ChAdOx1 nCoV-19 was safe and immunogenic, supporting vaccination for those well controlled on ART.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据